Breaking News Instant updates and real-time market news.

ZGNX

Zogenix

$37.95

-0.3 (-0.78%)

08:25
11/29/17
11/29
08:25
11/29/17
08:25

Zogenix initiates Phase 3 trial of ZX008

Zogenix announced that the first child has enrolled in the Phase 3 clinical trial for the company's lead investigational therapy, ZX008, as an adjunctive treatment of seizures associated with Lennox-Gastaut syndrome, or LGS. The Phase 3 multicenter, global LGS trial is divided in two parts. Part 1 is a double-blind, placebo-controlled investigation to assess the safety, tolerability and efficacy of ZX008, low-dose fenfluramine, when added to a patient's current anti-epileptic therapy. The trial will include two dose levels of ZX008, as well as placebo. After establishing baseline seizure frequency for 4 weeks, randomized patients will be titrated to their dose over a 2-week titration period, followed by a 12-week fixed dose maintenance period. Zogenix is targeting a total of 225 patients in the trial. The primary endpoint of the clinical trial is change in the number of seizures that result in drops between baseline and the combined titration and maintenance periods at the 0.8 mg/kg/day dose. The key secondary endpoints include change in the number of seizures that result in drops between baseline and the combined titration and maintenance periods at the 0.2 mg/kg/day dose, and the proportion of patients achieving a 50 percent reduction in drop seizures. Part 2 of the clinical trial will be a 12-month open-label extension to evaluate the long-term safety, tolerability and effectiveness of ZX008.

  • 04

    Dec

ZGNX Zogenix
$37.95

-0.3 (-0.78%)

09/29/17
WBLR
09/29/17
UPGRADE
WBLR
Outperform
William Blair calls Zogenix data best to date in upgrade to Outperform
William Blair analyst Tim Lugo earlier today upgraded Zogenix (ZGNX) to Outperform from Market Perform saying the company's Dravet data is the best to date. Zogenix's ZX008 looks superior to GW Pharmaceuticals' (GWPH) cannabinoid candidate, Epidiolex, Lugo told investors in a research note. Shares of Zogenix are up 179% to $35.88 after the company this morning announced positive top-line results from its first Phase 3 trial for ZX008 for the treatment of Dravet syndrome. GW Pharmaceuticals is down 8% to $102.79 in afternoon trading.
10/03/17
MZHO
10/03/17
NO CHANGE
Target $51
MZHO
Buy
Zogenix price target raised to $51 from $28 at Mizuho
Mizuho analyst Difei Yang raised his price target for Zogenix (ZGNX) to $51 from $28 after it announced positive topline data for its pivotal phase III trial of ZX008 in Dravet Syndrome - Study 1. The analyst notes study 1 met its primary endpoint, with topline results indicating a clear dose response, efficacy appears better than GW Pharma's (GWPH) Epidiolex, and mechanism of action involving Sig-1R receptor could explain the higher specificity of ZX-008. Yang argues that these findings may allow ZX-008 to be positioned before Epidiolex as a treatment option for Dravet Syndrome patients. He reiterates a Buy rating on Zogenix's shares.
11/20/17
STFL
11/20/17
NO CHANGE
Target $55
STFL
Buy
Physicians expressed excitement for Zogenix epilepsy treatment, says Stifel
After hosting a panel to discuss new developments for rare epileptic conditions, Stifel analyst Annabel Samimy noted that physicians in the space said they believed there was a place for both Zogenix's (ZGNX) fenfluramine and GW Pharmaceuticals' (GWPH) Epidiolex, the two most advanced treatments for Dravet Syndrome and Lennox-Gastaut Syndrome. Excitement for their introductions was "palpable, particularly for fenfluramine," added Samimy, who has a Buy rating and $55 price target on Zogenix and does not cover GW Pharmaceuticals.
11/27/17
JMPS
11/27/17
INITIATION
Target $56
JMPS
Outperform
Zogenix initiated with an Outperform at JMP Securities
JMP Securities analyst Jason Butler started Zogenix with an Outperform rating and $56 price target, saying he thinks the potential for ZX008 in seizure disorders beyond Dravet syndrome is currently underappreciated.

TODAY'S FREE FLY STORIES

02:35
12/14/17
12/14
02:35
12/14/17
02:35
General news
FX Update: The dollar turned to consolidation »

FX Update: The dollar…

01:55
12/14/17
12/14
01:55
12/14/17
01:55
General news
FX Action: The USD index (DXY) fell 0.8% »

FX Action: The USD index…

23:00
12/13/17
12/13
23:00
12/13/17
23:00
General news
PBoC nudged rates higher »

PBoC nudged rates higher,…

LPSN

LivePerson

$11.05

-0.05 (-0.45%)

20:28
12/13/17
12/13
20:28
12/13/17
20:28
Initiation
LivePerson initiated at B. Riley FBR »

LivePerson initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

HUSKF

Husky Energy

$12.42

-0.1177 (-0.94%)

20:26
12/13/17
12/13
20:26
12/13/17
20:26
Upgrade
Husky Energy rating change at Goldman Sachs »

Husky Energy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COP

ConocoPhillips

$51.68

-0.28 (-0.54%)

20:25
12/13/17
12/13
20:25
12/13/17
20:25
Upgrade
ConocoPhillips rating change at Goldman Sachs »

ConocoPhillips upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

SAFM

Sanderson Farms

$167.64

0.64 (0.38%)

20:25
12/13/17
12/13
20:25
12/13/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

DB

Deutsche Bank

$19.33

-0.05 (-0.26%)

19:17
12/13/17
12/13
19:17
12/13/17
19:17
Hot Stocks
DBNY, DBTCA raise prime lending rate to 4.5% from 4.25% »

Deutsche Bank announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$38.04

-0.06 (-0.16%)

18:47
12/13/17
12/13
18:47
12/13/17
18:47
Hot Stocks
AT&T and Communications Workers of America reach tentative agreement »

AT&T Mobility has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$63.47

0.19 (0.30%)

18:33
12/13/17
12/13
18:33
12/13/17
18:33
Hot Stocks
Bristol-Myers granted exclusive license by Ono Pharma to develop ONO-4578 »

Bristol-Myers and Ono…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 05

    Mar

WFC

Wells Fargo

$59.40

-0.93 (-1.54%)

18:15
12/13/17
12/13
18:15
12/13/17
18:15
Hot Stocks
Breaking Hot Stocks news story on Wells Fargo »

Wells Fargo raises prime…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

HBAN

Huntington Bancshares

$14.58

-0.23 (-1.55%)

18:10
12/13/17
12/13
18:10
12/13/17
18:10
Hot Stocks
Huntington Bancshares raises prime rate to 4.5% from 4.25% »

Huntington Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASB

Associated Banc-Corp

$25.10

-0.2 (-0.79%)

18:06
12/13/17
12/13
18:06
12/13/17
18:06
Hot Stocks
Breaking Hot Stocks news story on Associated Banc-Corp »

Associated Banc-Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBS

UBS

$17.90

0.035 (0.20%)

18:05
12/13/17
12/13
18:05
12/13/17
18:05
Periodicals
UBS Wealth Management president Zeltner close to stepping down, Bloomberg says »

UBS Wealth Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$36.64

0.06 (0.16%)

18:03
12/13/17
12/13
18:03
12/13/17
18:03
Hot Stocks
Pfizer announces FDA approves IXIFI, a biosimilar to Remicade »

Pfizer announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jan

CNP

CenterPoint Energy

$28.40

0.02 (0.07%)

18:03
12/13/17
12/13
18:03
12/13/17
18:03
Hot Stocks
CenterPoint Energy raises quarterly dividend 4% to 27.75c per share »

CenterPoint Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDXG

MiMedx

$11.99

-0.26 (-2.12%)

18:03
12/13/17
12/13
18:03
12/13/17
18:03
Recommendations
MiMedx analyst commentary at Piper Jaffray »

Piper reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

CE

Celanese

$108.31

1.34 (1.25%)

18:01
12/13/17
12/13
18:01
12/13/17
18:01
Hot Stocks
Celanese raises acetyl intermediates products prices »

Raises price on Vinyl…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAL

Western Alliance

$57.30

-1.25 (-2.13%)

18:01
12/13/17
12/13
18:01
12/13/17
18:01
Hot Stocks
Western Alliance: Sarver to transition from chairman, CEO to exec chairman in Q1 »

Western Alliance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USB

U.S. Bancorp

$54.60

-0.9 (-1.62%)

18:01
12/13/17
12/13
18:01
12/13/17
18:01
Hot Stocks
U.S. Bancorp raises prime lending rate to 4.50% from 4.25%, effective Dec 14 »

U.S. Bancorp last…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

WBS

Webster Financial

$56.16

-0.73 (-1.28%)

18:00
12/13/17
12/13
18:00
12/13/17
18:00
Hot Stocks
Webster raises prime lending rate to 4.5% from 4.25% »

Webster Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

HSBC

HSBC

$51.44

0.89 (1.76%)

17:56
12/13/17
12/13
17:56
12/13/17
17:56
Hot Stocks
Breaking Hot Stocks news story on HSBC »

HSBC raises prime,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTR

Aqua America

$37.59

0.32 (0.86%)

17:47
12/13/17
12/13
17:47
12/13/17
17:47
Hot Stocks
Aqua America names CEO Christopher Franklin as board chairman »

Aqua America announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

MSFT

Microsoft

$85.35

-0.23 (-0.27%)

17:38
12/13/17
12/13
17:38
12/13/17
17:38
Hot Stocks
Microsoft launches new AI-powered search features for Bing »

Microsoft announced in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

TCF

TCF Financial

$20.24

-0.16 (-0.78%)

17:36
12/13/17
12/13
17:36
12/13/17
17:36
Hot Stocks
Breaking Hot Stocks news story on TCF Financial »

TCF Financial raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.